HCG

Healthcare Global Enterprises Share Price

 

 

Invest in Healthcare Global Enterprises with 3.32X leverage

Invest with MTF

Performance

  • Low
  • ₹577
  • High
  • ₹614
  • 52 Week Low
  • ₹473
  • 52 Week High
  • ₹805
  • Open Price₹585
  • Previous Close₹586
  • Volume216,084
  • 50 DMA₹640.95
  • 100 DMA₹654.58
  • 200 DMA₹630.86

Investment Returns

  • Over 1 Month -4.36%
  • Over 3 Month -19.82%
  • Over 6 Month -0.92%
  • Over 1 Year + 18.74%

Smart Investing Starts Here Start SIP with Healthcare Global Enterprises for Steady Growth!

Invest Now

Healthcare Global Enterprises Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 454.5
  • PEG Ratio
  • -6.7
  • Market Cap Cr
  • 8,622
  • P/B Ratio
  • 9.4
  • Average True Range
  • 23.41
  • EPS
  • 1.93
  • Dividend Yield
  • 0
  • MACD Signal
  • -21.92
  • RSI
  • 48.33
  • MFI
  • 37.18

Healthcare Global Enterprises Financials

Healthcare Global Enterprises Technicals

EMA & SMA

Current Price
₹611.45
+ 25.9 (4.42%)
pointer
  • Bearish Moving Average 9
  • Bullish Moving Average 7
  • 20 Day
  • ₹606.89
  • 50 Day
  • ₹640.95
  • 100 Day
  • ₹654.58
  • 200 Day
  • ₹630.86

Resistance and Support

600.75 Pivot Speed
  • R3 661.75
  • R2 637.85
  • R1 624.65
  • S1 587.55
  • S2 563.65
  • S3 550.45

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Healthcare Global Enterprises Ltd. (HCG) is India’s largest provider of cancer care, operating a network of specialized hospitals across the country. It offers advanced oncology treatments, including radiation, chemotherapy, and surgical oncology, focusing on personalized patient care.

Healthcare Global Ents. has an operating revenue of Rs. 2,478.24 Cr. on a trailing 12-month basis. An annual revenue growth of 17% is outstanding, Pre-tax margin of 3% needs improvement, ROE of 4% is fair but needs improvement. The company has a debt to equity of 66%, which is bit higher. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 24 which is a POOR score indicating inconsistency in earnings, a RS Rating of 51 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at E which indicates heavy supply, Group Rank of 128 indicates it belongs to a poor industry group of Medical-Hospitals and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Healthcare Global Enterprises Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-17 Rights issue of Equity Shares
2026-02-05 Quarterly Results
2025-11-12 Quarterly Results
2025-08-01 Quarterly Results
2025-05-24 Audited Results

Healthcare Global Enterprises F&O

Healthcare Global Enterprises Shareholding Pattern

63.77%
15.08%
0.54%
3.22%
0%
11.2%
6.19%

About Healthcare Global Enterprises

  • NSE Symbol
  • HCG
  • BSE Symbol
  • 539787
  • ISIN
  • INE075I01017

Similar Stocks to Healthcare Global Enterprises

Healthcare Global Enterprises FAQs

Healthcare Global Enterprises share price is ₹611 As on 12 February, 2026 | 04:56

The Market Cap of Healthcare Global Enterprises is ₹8621.5 Cr As on 12 February, 2026 | 04:56

The P/E ratio of Healthcare Global Enterprises is 454.5 As on 12 February, 2026 | 04:56

The PB ratio of Healthcare Global Enterprises is 9.4 As on 12 February, 2026 | 04:56

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23